drugset
drugset / Trial / NCT03973827

Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed with Type I Diabetes

NCT03973827 ↗

Phase 1/2 Completed 15 enrolled NextCell Pharma Ab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

An open label, parallel single centre trial of Wharton's Jelly derived allogenic mesenchymal stromal cells repeated treatment to preserve endogenous insulin production in adult patients diagnosed with type 1 diabetes

Timeline

Start
2019-05-17
Primary completion
2020-12-10
Completion
2024-11-20

Drugs

EvaluationDrugModalityDoseRoute
Subject ProTrans Cell therapy 25 cells —
Subject ProTrans Cell therapy 100 cells —
Subject ProTrans Cell therapy 200 cells —

Indications

type 1 diabetes mellitus